Neogen Corp (NEOG) stock
NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)
Close on Nov 17, 2026Market cap $2.38BP/E –Yield –
Neogen total assets
Total assets on the balance sheet at the end of each period.
Neogen's total assets was $3.30B at Aug 31, 2026. For fiscal 2026 it was $3.35B, down 2.8% from the year before. Over ten years it grew 22.2% a year on average. The highest annual figure on record is $4.55B in fiscal 2023.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $3.35B | -2.8% |
| FY2025 | May 31, 2025 | $3.44B | -24.3% |
| FY2024 | May 31, 2024 | $4.55B | -0.1% |
| FY2023 | May 31, 2023 | $4.55B | +358.7% |
| FY2022 | May 31, 2022 | $992.93M | +7.9% |
| FY2021 | May 31, 2021 | $920.19M | +15.4% |
| FY2020 | May 31, 2020 | $797.18M | +14.6% |
| FY2019 | May 31, 2019 | $695.74M | +12.6% |
| FY2018 | May 31, 2018 | $618.01M | +17.0% |
| FY2017 | May 31, 2017 | $528.41M | +17.4% |
| FY2016 | May 31, 2016 | $449.94M | +14.7% |
| FY2015 | May 31, 2015 | $392.18M | +13.6% |
| FY2014 | May 31, 2014 | $345.30M | +18.8% |
| FY2013 | May 31, 2013 | $290.56M | +15.5% |
| FY2012 | May 31, 2012 | $251.60M | +14.5% |
| FY2011 | May 31, 2011 | $219.66M | +21.9% |
| FY2010 | May 31, 2010 | $180.23M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $3.30B | -2.2% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $3.35B | -2.8% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $3.36B | -16.8% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $3.36B | -17.1% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $3.38B | -25.0% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $3.44B | -24.3% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $4.04B | -11.9% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $4.05B | -11.9% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $4.50B | -1.3% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $4.55B | -0.1% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $4.58B | +1.6% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $4.60B | +0.9% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $4.56B | +366.7% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $4.55B | +358.7% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $4.51B | +359.5% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $4.56B | +371.4% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $977.41M | +4.9% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $992.93M | +7.9% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $981.21M | +11.5% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $967.93M | +14.5% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $932.11M | +13.5% |
| Q4 FY2021CQ2 2021 | May 31, 2021 | $920.19M | +15.4% |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | $880.22M | +13.8% |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | $845.63M | +12.7% |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | $821.59M | +13.9% |
| Q4 FY2020CQ2 2020 | May 31, 2020 | $797.18M | +14.6% |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | $773.50M | +15.0% |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | $750.59M | +13.6% |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | $721.14M | +12.5% |
| Q4 FY2019CQ2 2019 | May 31, 2019 | $695.74M | +12.6% |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | $672.59M | +12.9% |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | $660.49M | +13.7% |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | $640.93M | +17.1% |
| Q4 FY2018CQ2 2018 | May 31, 2018 | $618.01M | +17.0% |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | $595.60M | +17.4% |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | $581.03M | +19.2% |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | $547.33M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | $528.41M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | $507.30M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | $487.31M | – |
See a number that looks wrong?